Date of Award
Type 1 Diabetes, Improve Outcomes
Term of Grant
Safety evaluation of chronic and sub-chronic use of the glucagon analogue ZP4207 for the treatment of hypoglycemia
Funding to augment Zealand Pharma’s efforts to expand the safety studies of a novel stable glucagon analog, ZP4207, to allow the analog be used chronically for various indications aimed at improving health outcomes for people with type 1 diabetes.